Study finds COVID-19 convalescent plasma therapy safe, with 76% patients improving
Use of antihypertensive drugs generates pressure-packed debate in COVID-19 era
Lockdown: we need to experiment with reopenings now to prevent a second wave
Nicotine therapy for coronavirus: the evidence is weak and contradictory
Antibody injections could fight COVID-19 infections – an infectious disease expert explains the prospects
From the research lab to your doctor's office – here's what happens in phase 1, 2, 3 drug trials
Americans' deepening financial stress will make the coronavirus a lot harder to contain
Lilly begins trial of COVID-19 antibody treatment
Aveo’s Tivozanib Gets FDA Nod For New Drug Application To Treat Kidney Cancer
Gilead Sinks 3% On New Remdesivir Data; Analysts Stay Sidelined
New remdesivir study leaves clinicians guessing about its efficacy
The contradiction in BlackRock’s China and ESG focuses
Solubilizer Captisol enables body to absorb authorized COVID-19 drug therapy
Convenient spit test helps women assess cancer risk from the comfort of their own homes
Abiomed’s Heart Pump Gets FDA Emergency Use Status For Covid-19 Patients
FDA approval for Brilinta, EU recommendation for Lynparza
Eli Lilly Starts Dosing Patients In World's First Covid-19 Antibody Trial
US Open – Stocks fall as China hints at reneging on trade deal, ISM shows worst is over, US protests spread, Oil slips, Gold drops on...
Study shows hydroxychloroquine’s harmful effects on heart rhythm
IPOs abound in the time of coronavirus, as Forma Therapeutics pencils in $150M Nasdaq debut
Eli Lilly’s Taltz Injection Gets FDA Nod For Inflammatory Spine Arthritis Treatment
Immutep Surges In Pre-Market On Positive Efti Cancer Data
Drugmaker Abbvie Teams Up With Jacobio To Develop Cancer Inhibitor
Macro Briefing | 1 June 2020
Pfizer Loses 6% On Disappointing Ibrance Breast Cancer Outcome
Minerva Shares Tank 72% As Schizophrenia Drug Misses Trial Goals
Exclusive: Sanofi stops enrolling COVID-19 patients in hydroxychloroquine trials
Efgartigimod's Positive Data Is Good News for Momenta’s Nipocalimab
Chimeron Bio & George Mason NCBID partner on COVID-19 vaccine using ChaESARTM technology
US Close – Risk rally resumes as Trump walks fine line, Oil extends higher after phase-one deal left alone, Gold softer post Trump